AMIHOT

AMIHOT

Acute Myocardial Infarction with Hyperoxemic Therapy. A clinical study evaluating the safety of intracoronary hyperoxaemic therapy after primary percutaneous coronary intervention (PCI) for acute myocardial infarction.
Conclusion Preliminary data suggest that the trends toward improved ST-segment data are in keeping with improved microcirculation.
References in periodicals archive ?
Simon Dixon, MD, chair of cardiovascular medicine at Beaumont Hospital and an investigator for this study, was involved in the previous SSO2 Therapy trial, AMIHOT II.
This second generation system improves upon our previous system by making SSO2 Therapy easier to administer in the cath lab, and we anticipate even better results than achieved in AMIHOT II.
The first generation system to deliver SSO2 Therapy received the CE Mark and was successful in meeting the safety and effectiveness endpoints in the AMIHOT II trial.
The successful results from TherOx's pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), were presented at the 19th Annual Transcatheter Cardiovascular Therapeutics scientific symposium in October 2007 and the company recently completed a U.
a privately held medical device company, announced it has successfully met its endpoints for its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), which studied SuperOxygenation Therapy for Acute Myocardial Infarction (AMI) patients.
AMIHOT II showed superiority of the adjunctive administration of SuperOxygenation Therapy over the current AMI standard of care alone - available drug regimens coupled with urgent Percutaneous Coronary Intervention (PCI) - by demonstrating a significant reduction in infarct size for patients treated within six hours from symptom onset for anterior AMI.
The positive results shown in AMIHOT II significantly expand AMI treatment options for interventional cardiologists and their patients affected by large heart attacks.
AMIHOT II Studied SuperOxygenation Therapy for Myocardial Salvage Intervention
THEROX), a privately held medical device company, announced that it has successfully completed enrollment in its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy).
AMIHOT II was derived from a subset of the original AMIHOT study population consisting of anterior AMI patients treated within 6 hours from symptom onset.
presented results from the Acute Myocardial Infarction Hyperoxemic Therapy (AMIHOT) 269-patient trial on behalf of the AMIHOT Investigators at the Transcatheter Therapeutics (TCT) Conference in Washington, D.
The AMIHOT study was conducted at 23 sites in the United States and Europe.